In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17207 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von P Sittiwattanawong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research, Chulalongkorn University, B…. Hauptthemen laut MEDLINE: Enzyme-Linked Immunospot Assay, Patch Tests. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: The Ratchadapiseksomphot Endowment Fund, Faculty of Medicine, Chulalongkorn University, Health Systems Research Institute.
Abstract (Originalsprache)
Drug causality assessment in severe cutaneous adverse reactions (SCARs) remains challenging. We investigated the usefulness of in‐vivo drug patch tests (PT), ex‐vivo interferon (IFN)‐γ enzyme‐linked immunospot (ELISpot) assay, and lymphocyte transformation test (LTT) in 30 SCARs patients within the past 36 months. Drug PT yielded a 20% positivity rate ( n = 6), while IFN‐γ ELISpot and LTT showed positive rates of 56.67% ( n = 17) and 41.38% ( n = 12), respectively. Combining the three tests resulted in an overall positive rate of 66.67% ( n = 20) of cases. IFN‐γ ELISpot offered additional positivity, especially with oxypurinol. Employing a combined diagnostic approach may enhance the chances of obtaining a positive result.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research, Chulalongkorn University, Bangkok, Thailand.
- Center for Excellence in Biostatistics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research, Chulalongkorn University, Bangkok, Thailand.
- Division of Immunology, Department of Microbiology, Faculty of Medicine, Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: K Charoenchaipiyakul, P Asawanonda, P Rerknimitr
Förderung
- The Ratchadapiseksomphot Endowment Fund, Faculty of Medicine, Chulalongkorn University
- Health Systems Research Institute
Zitieren
APA
Sittiwattanawong, P., Kantikosum, K., Charoenchaipiyakul, K., Pootongkam, S., Asawanonda, P., Kerr, S. J., Thantiworasit, P., Sodsai, P., Hirankarn, N., Klaewsongkram, J., & Rerknimitr, P. (2024). In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17207
Vancouver
Sittiwattanawong P, Kantikosum K, Charoenchaipiyakul K, Pootongkam S, Asawanonda P, Kerr SJ, et al. In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17207
BibTeX
@article{Sittiwattanawong2024,
author = {Sittiwattanawong, P and Kantikosum, K and Charoenchaipiyakul, K and Pootongkam, S and Asawanonda, P and Kerr, S J and Thantiworasit, P and Sodsai, P and Hirankarn, N and Klaewsongkram, J and Rerknimitr, P},
title = {In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17207}
}
EUVIMED